Related references
Note: Only part of the references are listed.Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Osteonecrosis of the jaws induced by anti-RANK ligand therapy
K. H. Taylor et al.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (2010)
The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis
Athanasios D. Anastasilakis et al.
CLINICAL ENDOCRINOLOGY (2010)
Molecular Targets of the Nitrogen Containing Bisphosphonates: The Molecular Pharmacology of Prenyl Synthase Inhibition
J. E. Dunford
CURRENT PHARMACEUTICAL DESIGN (2010)
The effect of intramuscular vitamin D (cholecalciferol) on serum 25OH vitamin D levels in older female acute hospital admissions
C. Nugent et al.
IRISH JOURNAL OF MEDICAL SCIENCE (2010)
Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer
Chris R. Cardwell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis
Bo Abrahamsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Osteonecrosis of the Jaw in a Patient on Denosumab
Tara L. Aghaloo et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2010)
The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis
Alison M. Betts et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lasofoxifene in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis
F. Borgstrom et al.
OSTEOPOROSIS INTERNATIONAL (2010)
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXA®
F. Borgstrom et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database
G. Breart et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Development and use of FRAXA® in osteoporosis
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort
Jane Green et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis
Mark J. Bolland et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Predicting Risk of Osteoporotic Fracture in Men and Women in England and Wales: Prospective Derivation and Validation of QFractureScores
P. Mikosch
JOURNAL FUR MINERALSTOFFWECHSEL (2010)
Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years
J. Y. Reginster et al.
BONE (2009)
Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
Dennis B. Henriksen et al.
BONE (2009)
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study
S. T. Harris et al.
BONE (2009)
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies
S. A. Stoch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women
Olivier Bruyere et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2009)
Wnt signaling as a therapeutic target for bone diseases
Luke H. Hoeppner et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture
Erik Fink Eriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effects of Arzoxifene on Bone Mineral Density and Endometrium in Postmenopausal Women with Normal or Low Bone Mass
M. Bolognese et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Reports of Esophageal Cancer with Oral Bisphosphonate Use
Diane K. Wysowski
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Developments in the scientific understanding of osteoporosis
Nancy E. Lane et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Jacques Yves Gauthier et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Stuart L. Silverman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
The effect of raloxifene treatment in postmenopausal women with CKD
Areef Ishani et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
FRAX™ and the assessment of fracture probability in men and women from the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Case finding for the management of osteoporosis with FRAX® -: assessment and intervention thresholds for the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Therapy of osteoporosis with calcium and vitamin D
Bess Dawson-Hughes et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bone mass is inversely proportional to Dkk1 levels in mice
Bryan T. MacDonald et al.
BONE (2007)
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate
Olivier Bruyere et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial
Sophie A. Jamal et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Disassociation of bone resorption and formation by GLP-2 - A 14-day study in healthy postmenopausal women
Dennis B. Henriksen et al.
BONE (2007)
Optimal vitamin D status for the prevention and treatment of osteoporosis
Michael F. Holick
DRUGS & AGING (2007)
Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older
Ego Seeman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
Janne Komi et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2006)
Effects of calcium supplementation on clinical fracture and bone structure - Results of a 5-year, double-blind, placebo-controlled trial in elderly women
RL Prince et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Calcium plus vitamin D supplementation and the risk of fractures
RD Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of short-term alendronate on bone mineral density in haemodialysis patients
JB Wetmore et al.
NEPHROLOGY (2005)
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
JY Reginster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: The Fracture Intervention Trial
SA Quandt et al.
MAYO CLINIC PROCEEDINGS (2005)
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate
MJ Seibel et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
PJ Meunier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
PD Delmas et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Positive association between 25-hydroxy, vitamin D levels and bone mineral density: A population-based study of younger and older adults
HA Bischoff-Ferrari et al.
AMERICAN JOURNAL OF MEDICINE (2004)
A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NoNOF) Study
RH Harwood et al.
AGE AND AGEING (2004)
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial
PD Delmas et al.
BONE (2003)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
JE Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Epidemiology and outcomes of osteoporotic fractures
SR Cummings et al.
LANCET (2002)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)